Rare Lipid Gene Variants Found in MASLD Patients Drive Worse Liver Damage

Fatty liver disease (MASLD) is strongly tied to metabolic dysfunction and abnormal lipid metabolism, but the role of rare inherited lipid gene mutations in shaping disease severity has remained poorly characterized. This study from the NASH Clinical Research Network (NASH-CRN) is among the most comprehensive genomic investigations of monogenic dyslipidemia variants in a well-characterized MASLD cohort, using whole exome sequencing and targeted whole genome sequencing in 3,358 biopsy-proven patients recruited across multiple U.S. centers from 2004 to 2020.

Researchers focused on six genes whose pathogenic variants cause either hypobetalipoproteinemia (low apoB-containing lipoproteins) or familial hypercholesterolemia (elevated LDL): APOB, MTTP, PCSK9, ANGPTL3, LDLR, and LDLRAP1. Starting from 2,027 ClinVar-annotated pathogenic or likely pathogenic (P/LP) variants across these six genes, the team mapped which variants were detectable in their sequencing data and identified carriers in the cohort. Of the 2,027 variants screened, only 22 were present in the NASH-CRN dataset, found in 24 patients — 12 APOB carriers, 10 LDLR carriers, 1 ANGPTL3 carrier, and 1 MTTP carrier. This represents a carrier prevalence of under 1%, indicating these monogenic conditions are not enriched in MASLD populations.

For the APOB carriers — whose variants impair hepatic secretion of apoB-containing lipoproteins, causing fat to accumulate in liver cells — liver histology was significantly worse than in matched controls. Steatosis grade averaged 2.4 vs. 1.7 (p=0.0028), and NAFLD Activity Score (NAS) was 4.9 vs. 3.8 (p=0.04). Fibrosis stage trended higher (1.2 vs. 1.1) and ALT was numerically elevated (87.4 vs. 58.1 U/L) but neither reached statistical significance. Consistent with the biology of hypobetalipoproteinemia, APOB carriers had strikingly lower LDL-cholesterol (51 vs. 147.8 mg/dL, p=6.1×10⁻⁹) and lower triglycerides (91.5 vs. 160.6 mg/dL, p=0.0028).

For LDLR carriers — whose variants cause familial hypercholesterolemia by impairing LDL receptor-mediated catabolism — steatosis, NAS, fibrosis stage, and LDL-c were all numerically higher than controls, but none of these differences reached statistical significance, likely reflecting the small sample size (n=10). Statin use was accounted for by imputing an approximate 48% LDL reduction for those on therapy. No PCSK9 or LDLRAP1 carriers were identified in the cohort.

The study's design included matching approximately four controls per carrier on age, sex, race/ethnicity, and BMI to isolate the effect of variant carrier status from major confounders. The biological rationale for APOB findings is compelling: when apoB-containing lipoprotein secretion is impaired, hepatic fat cannot be exported, creating an environment of triglyceride accumulation that parallels the more severe steatosis observed. These results build on prior work by Vilar-Gomez et al. and others suggesting heterozygous hypobetalipoproteinemia worsens liver injury, particularly in the context of insulin resistance.